Section 4 of 6
Clinical evidence
195 evidence topics · 31 sources
Study summaries
FORTIFI-HN01
Objective
Study purpose in the ClinicalTrials.gov record
Phase 2 and phase 3 objectives in the EU trial record
Study question in the updated trial-in-progress poster
Location and study date
Study dates and sites in the ClinicalTrials.gov record
| Study characteristic | Quoted record |
|---|---|
| Study start (actual) | “2025-01-28” |
| Primary completion (estimated) | “2028-04” |
| Study completion (estimated) | “2029-07” |
| Sites | “This study has 231 locations” |
Enrollment regions in the updated trial-in-progress poster
First enrollment in the annual report
Study design
Seamless phase 2 and phase 3 design in the ClinicalTrials.gov record
Blinding in the EU trial record
Stratification factors in the updated trial-in-progress abstract
Phase 2 dose decision rule in the initial trial-in-progress poster
Dose optimization run-in in the annual report
FDA dose-optimization guidance on randomized dose comparison
Eligibility criteria
Exclusion criteria in the ClinicalTrials.gov record
Primary site and histology in the EU trial record
HPV assay developer named in the EU trial record
| Third party | Quoted record |
|---|---|
| Organization | “Qiagen Manchester Limited” |
| Duty delegated by the sponsor | “Development of HPV DNA Assay” |
Prior-therapy criteria in the EU trial record
Measurable disease, performance status, and age in the EU trial record
Bleeding risk exclusion in the EU trial record
Central laboratory HPV confirmation in the initial trial-in-progress abstract
Central laboratory HPV confirmation in the updated trial-in-progress abstract
Key eligibility criteria in the updated trial-in-progress poster
Population description in the first-enrollment press release
Treatment
Treatment arms in the ClinicalTrials.gov record
| Arm | Quoted regimen |
|---|---|
| Phase 2 Arm A | “ficerafusp alfa 1500 mg QW + pembrolizumab 200 mg every 3 weeks (Q3W)” |
| Phase 2 Arm B | “ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W” |
| Phase 2 Arm C and Phase 3 Arm C (placebo comparator) | “placebo QW + pembrolizumab 200 mg Q3W” |
| Phase 3 OBD Arm | “ficerafusp alfa OBD + pembrolizumab 200 mg Q3W” |
Route, schedule, and duration in the updated trial-in-progress abstract
Selected phase 3 dose and phase 2 crossover in the updated trial-in-progress poster
Study outcomes
Rationale for using RECIST v1.1 objective response rate and overall survival as the primary endpoints
Primary endpoints in the ClinicalTrials.gov record
Primary endpoints in the EU trial record
Secondary endpoints in the ClinicalTrials.gov record
Patient-reported outcome endpoints in the ClinicalTrials.gov record
Endpoint roles and tumor assessment schedule in the updated trial-in-progress abstract
Endpoint roles in the updated trial-in-progress poster
Regulatory basis for the response and survival endpoints in the annual report
Regulatory basis in the first-enrollment press release
FDA endpoint guidance on objective response rate and overall survival
FDA draft guidance on one randomized trial for accelerated approval and verification of benefit
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment in the ClinicalTrials.gov record
Planned enrollment in the updated trial-in-progress abstract
Planned enrollment in the updated trial-in-progress poster
Description of analysis sets
Response analysis sets in the ClinicalTrials.gov record
Phase 2 participants contributing to the primary analyses in the annual report
Interim and final analyses in the trial-in-progress materials
Interim analysis timing in the third-quarter results press release
Results
Participant disposition
First enrollment in the press release
Completion of phase 2 and transition to phase 3 in the annual report
Phase 2 arm disposition in the updated trial-in-progress poster
Baseline characteristics
No evidence found.
Efficacy results
Phase 2 dose selection outcome in the press release
Data informing dose selection in the annual report
Biomarker basis for dose selection in the full-year results press release
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
FORTIFI-HN01 has reported no efficacy, safety, or baseline results; the phase 3 dose selection rests on company statements that it was informed by the open-label phase 1/1b data sets and by data from the phase 2 treatment arms. Accelerated approval would rest on an interim ORR analysis, with clinical benefit verified by OS in the same trial, the design FDA draft guidance calls the “one-trial” approach; FDA draft guidance states that preserving trial integrity is critical to that approach, and Bicara states that “interim and preliminary data may not be predictive of final results” and that confirmatory studies may not show clinical benefit. The control arm is placebo plus pembrolizumab 200 mg every 3 weeks, and participants treated at 1500 mg weekly in phase 2 contribute to the primary analyses while those treated at 750 mg weekly do not.
Verification of clinical benefit after accelerated approval in the annual report
Potential bias in a single-trial accelerated approval design in FDA draft guidance
BCA101X1101
Objective
Registry title and purpose
Dose escalation: safety, tolerability, and maximum tolerated dose
First-line HNSCC expansion cohort at 1500 mg weekly: safety and antitumor activity
Integrated analysis of the three first-line dose cohorts
Location and study date
Registry study dates
| Study characteristic | Quoted record |
|---|---|
| Study start (actual) | “2020-06-01” |
| Primary completion (estimated) | “2027-10-31” |
| Study completion (estimated) | “2028-03-30” |
Registry study sites
| Country | Quoted site |
|---|---|
| United States | “Moores Cancer Center UC San Diego Health” |
| United States | “Keck School of Medicine of USC” |
| United States | “University of California, Davis Comprehensive Cancer Center” |
| United States | “H. Lee Moffitt Cancer Center and Research Institute, Inc” |
| United States | “Dana Farber/Partners Cancer Care Inc” |
| United States | “Memorial Sloan Kettering” |
| United States | “Columbia University Herbert Irving Comprehensive Cancer Center” |
| United States | “Levine Cancer Institute” |
| United States | “Cleveland Clinic” |
| United States | “UPMC Hillman Cancer Center” |
| United States | “Rhode Island Hospital” |
| United States | “Medical University of South Carolina, Hollings Cancer Center” |
| United States | “Vanderbilt University Medical Center” |
| United States | “MD Anderson Cancer Center” |
| Australia | “Chris O'Brien Lifehouse” |
| Australia | “Calvary Mater Newcastle” |
| Australia | “Austin Hospital” |
| Australia | “Peter MacCallum Cancer Centre” |
| Canada | “Princess Margaret Cancer Centre” |
| Canada | “Centre hospitalier de l'Université de Montréal (CHUM)” |
Dose escalation enrollment period and data cutoff
“Between June 25, 2020, and June 9, 2022, 61 patients were enrolled” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The data cutoff for the data reported was April 17, 2024.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-line 1500 mg weekly cohort enrollment period, data snapshot, and geography
First-line 750 mg weekly cohort data snapshot
First-line 2000 mg every 2 weeks cohort data snapshot
Integrated analyses of the first-line cohorts: data cutoffs
Study design
Registry design: nonrandomized, open-label, parallel assignment
| Study characteristic | Quoted record |
|---|---|
| Protocol number | “BCA101X1101” |
| Merck study identifier | “KEYNOTE-E28” |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |
Registry design: dose escalation (Part A) followed by expansion cohorts (Part B)
Dose escalation: parallel 3 + 3 design with backfilling
“Dose escalation in this first-in-human phase I clinical trial (BCA101X1101) followed a parallel 3 + 3 design for both ficerafusp alfa monotherapy and ficerafusp alfa in combination with pembrolizumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Backfilling of up to six additional patients was allowed once acceptable safety had been demonstrated for the respective dose level.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Once the first two dose levels of ficerafusp alfa monotherapy were determined to be safe, enrollment in the combination started.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-line HNSCC dose-expansion cohort reported separately from escalation
Three first-line HPV-negative dose-expansion cohorts under a Simon two-stage design
Rationale for the 750 mg weekly and 2000 mg every 2 weeks cohorts
Eligibility criteria
Registry criteria for the first-line HNSCC combination cohort (expansion cohort 2)
Registry criteria for the HNSCC cohort with CPS less than 1 (expansion cohort 6)
Registry criteria common to all cohorts
First-line 1500 mg weekly cohort: published eligibility, PD-L1 assay, and HPV determination
Integrated first-line HPV-negative analysis: key inclusion criteria
First-line 750 mg weekly and 2000 mg every 2 weeks cohorts: HPV-negative population
Dose escalation combination cohort eligibility
“For the dose-escalation cohort receiving ficerafusp alfa in combination with pembrolizumab, tumor types included recurrent unresectable or metastatic (R/M) HNSCC and SCAC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were eligible regardless of the number of previous lines of systemic therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“EGFR tumor tissue expression testing was not required for participation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were ineligible if they had a history of gastrointestinal bleeding 4 weeks prior to enrollment, a history of clinically significant cardiac valvular disease, previous treatment with anti–TGF-β therapy, or a prior history of grade ≥2 intolerance or hypersensitivity reaction to cetuximab or other anti-EGFR therapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Registry arms
| Arm | Quoted arm description |
|---|---|
| BCA101 monotherapy | “Route: IV Infusion Frequency: QW Current Dose: 1500mg” |
| BCA101 plus pembrolizumab | “Route: IV Infusion Frequency: Q3W Dose: 200mg” |
Dose escalation: dose range, starting doses, and infusion
“At escalating doses in a parallel 3 + 3 design, patients with EGFR-driven advanced solid tumors received weekly intravenous ficerafusp alfa as monotherapy (64–1,500 mg) or in combination (240–1,500 mg) with pembrolizumab (200 mg i.v. every 3 weeks).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The starting dosage of ficerafusp alfa in monotherapy for patients enrolled in the study was set at 64 mg i.v. administered continuously once weekly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The selected starting dosage followed the International Council for Harmonization S9 guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ficerafusp alfa was administered as an infusion over 120 minutes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The starting dosage of ficerafusp alfa in combination with pembrolizumab was 240 mg i.v. once weekly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pembrolizumab 200 mg i.v. was administered after ficerafusp alfa as a 30-minute infusion every 3 weeks (cycle length, 21 days).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“64, 240, 500, 750, 800, 1,000, 1,250, and 1,500 mg” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-line 1500 mg weekly regimen and dose modification rules
First-line 2000 mg every 2 weeks regimen
Escalation and expansion regimens in the integrated analysis
Study outcomes
Rationale for using dose-limiting toxicities and adverse events as the primary endpoints
Registry primary outcomes
Registry secondary outcomes and response criteria
| Outcome | Quoted description |
|---|---|
| Objective response rate | “Determine objective response rate in each part of the study, per RECIST v1.1 and iRECIST” |
| Clinical benefit rate | “Determine clinical benefit rate in each part of the study, per RECIST v1.1 and iRECIST” |
| Progression-free survival | “Determine PFS in each part of the study, per RECIST v1.1 and iRECIST” |
| Duration of response | “Determine duration of response in each part of the study, per RECIST v1.1 and iRECIST” |
| Overall survival | “Determine survival rates in each part of the study.” |
| Immunogenicity | “Incidence and titer of anti-drug-antibodies” |
Dose escalation: dose-limiting toxicity as the primary endpoint
“The primary endpoint was the incidence of dose-limiting toxicities (DLT).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“DLTs were defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications occurring within the first 21 days of treatment with ficerafusp alfa” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secondary objectives included the characterization of the pharmacokinetic (PK) and immunogenicity profile of ficerafusp alfa and preliminary antitumor activity of ficerafusp alfa as monotherapy and in combination with pembrolizumab as assessed by the investigator by RECIST version 1.1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-line 1500 mg weekly cohort: safety as the primary endpoint and efficacy endpoint definitions
Depth of response: definition
Depth of response: rationale for exploratory analysis
Objective response rate and depth of response as support for the pivotal interim analysis
Statistical analysis description
Number of participants (Planned and analyzed)
Registry planned enrollment across all cohorts
| Study characteristic | Quoted record |
|---|---|
| Enrollment (estimated) | “473” |
First-line 1500 mg weekly cohort: Simon two-stage sample size and participants analyzed
First-line 750 mg weekly cohort: participants analyzed
First-line 2000 mg every 2 weeks cohort: participants analyzed
Integrated first-line HPV-negative analyses: participants analyzed and follow-up
Description of analysis sets
Dose escalation analysis sets
“Descriptive statistics were used to summarize all patient characteristics, treatment administration and compliance, efficacy endpoints, and safety parameters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The safety set included all patients who received at least one dose of study treatment, ficerafusp alfa or pembrolizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The dose-determining set included all patients in the safety set who enrolled during dose escalation and either experienced a DLT at any time during the DLT evaluation period (first 21 days) or had all required safety assessments without experiencing a DLT within the DLT evaluation period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The efficacy-evaluable set included all patients who received at least one dose of study treatment and had at least one post-baseline tumor assessment as defined in the protocol at or beyond the first post-baseline visit for tumor assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If a patient had progressive disease before the first post–baseline assessment visit, they were also included in the efficacy-evaluable set.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The PK analysis set consisted of all patients who had at least one blood sample providing evaluable PK data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The duration of response analysis was performed using Kaplan–Meier methods.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-line 1500 mg weekly cohort analysis sets and HPV subgroups
Integrated first-line analysis restricted to HPV-negative participants
Pooled efficacy-evaluable set for the depth of response analysis
Results
Participant disposition
Dose escalation: participants excluded from the efficacy-evaluable set
“Of the 46 patients treated with ficerafusp alfa monotherapy, four patients did not have a post-baseline assessment and were excluded from the efficacy-evaluable population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 15 patients treated with ficerafusp alfa in combination with pembrolizumab, 13 patients were RECIST 1.1 evaluable, and two patients discontinued treatment because of adverse events before the first post-baseline efficacy assessment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-line 1500 mg weekly cohort: screening, treatment status, and follow-up
First-line 1500 mg weekly cohort: reasons for treatment or study discontinuation
| Status or reason | Safety set (N = 42), No. (%) | Efficacy-evaluable set (n = 39), No. (%) |
|---|---|---|
| Treatment ongoing | “3 (7)” | “3 (7)” |
| Treatment discontinuation | “39 (93)” | “36 (92)” |
| Treatment discontinuation: progression of disease | “21 (50)” | “20 (51)” |
| Treatment discontinuation: adverse event | “10 (24)” | “8 (21)” |
| Treatment discontinuation: patient withdrawal | “5 (12)” | “5 (13)” |
| Treatment discontinuation: investigator discretion | “3 (7)” | “3 (8)” |
| Study follow-up ongoing | “12 (29)” | “12 (31)” |
| Study follow-up discontinued | “30 (71)” | “27 (69)” |
| Study follow-up discontinued: death | “29 (69)” | “26 (67)” |
| Study follow-up discontinued: patient withdrawal | “1 (2)” | “1 (3)” |
| Study follow-up discontinued: lost to follow-up | “0” | “0” |
First-line 750 mg weekly cohort: participant not evaluable for efficacy
First-line 1500 mg weekly cohort: participants on treatment at the most recent data cut
Baseline characteristics
First-line HPV-negative dose cohorts at the March 2026 data cut
| Characteristic | 750 mg QW (N=31) | 1500 mg QW (N=30) | 2000 mg Q2W (N=30) |
|---|---|---|---|
| Age, median (min-max) | “64 (28-78)” | “63 (31-84)” | “63 (32-94)” |
| Male, n (%) | “20 (65)” | “19 (63)” | “20 (67)” |
| Female, n (%) | “11 (35)” | “11 (37)” | “10 (33)” |
| Oral cavity, n (%) | “19 (61)” | “14 (47)” | “19 (63)” |
| Oropharynx (HPV negative), n (%) | “4 (13)” | “8 (27)” | “6 (20)” |
| Hypopharynx, n (%) | “5 (16)” | “4 (13)” | “2 (7)” |
| Larynx, n (%) | “3 (10)” | “4 (13)” | “3 (10)” |
| CPS 1-19, n (%) | “12 (39)” | “15 (50)” | “15 (50)” |
| CPS ≥20, n (%) | “19 (61)” | “15 (50)” | “15 (50)” |
| Locoregional only, (%) | “16 (52)” | “9 (30)” | “19 (63)” |
| Distant metastatic only, (%) | “5 (16)” | “7 (23)” | “5 (17)” |
| Locoregional and distant metastatic, (%) | “10 (32)” | “14 (47)” | “6 (20)” |
| Target lesion diameter (mm) at baseline, median (min-max) | “41 (11-131)” | “49 (10-133)” | “33 (10-187)” |
| Sum of target lesion diameters >50 mm, n (%) | “10 (32)” | “14 (47)” | “11 (37)” |
| Sum of target lesion diameters >70 mm, n (%) | “4 (13)” | “8 (27)” | “7 (23)” |
| ECOG PS 0, n (%) | “11 (35)” | “11 (37)” | “10 (33)” |
| ECOG PS 1, n (%) | “20 (65)” | “19 (63)” | “20 (67)” |
First-line 1500 mg weekly cohort by HPV status
| Characteristic | Participants (N = 42) | HPV-positive (n = 12) | HPV-negative (n = 30) |
|---|---|---|---|
| Age, years, median (range) | “63 (31-84)” | “65 (48-77)” | “63 (31-84)” |
| Male, No. (%) | “30 (71)” | “11 (92)” | “19 (63)” |
| Female, No. (%) | “12 (29)” | “1 (8)” | “11 (37)” |
| White/Caucasian, No. (%) | “34 (81)” | “10 (83)” | “24 (80)” |
| Black or African American, No. (%) | “3 (7)” | “1 (8)” | “2 (7)” |
| Asian, No. (%) | “1 (2)” | “0” | “1 (3)” |
| Multiple races, No. (%) | “1 (2)” | “0” | “1 (3)” |
| Race not reported, No. (%) | “3 (7)” | “1 (8)” | “2 (7)” |
| ECOG performance status 0, No. (%) | “15 (36)” | “4 (33)” | “11 (37)” |
| ECOG performance status 1, No. (%) | “27 (64)” | “8 (67)” | “19 (63)” |
| Oropharynx, No. (%) | “20 (48)” | “12 (100)” | “8 (27)” |
| Oral cavity, No. (%) | “14 (33)” | “0” | “14 (47)” |
| Hypopharynx, No. (%) | “4 (10)” | “0” | “4 (13)” |
| Larynx, No. (%) | “4 (10)” | “0” | “4 (13)” |
| CPS at screening 1-19, No. (%) | “22 (52)” | “7 (58)” | “15 (50)” |
| CPS at screening ≥20, No. (%) | “20 (48)” | “5 (42)” | “15 (50)” |
| Locoregional only, No. (%) | “11 (26)” | “2 (17)” | “9 (30)” |
| Locoregional and distant metastatic, No. (%) | “17 (40)” | “3 (25)” | “14 (47)” |
| Distant metastatic only, No. (%) | “14 (33)” | “7 (58)” | “7 (23)” |
| Sum of target lesion diameters ≤50 mm, No. (%) | “24 (57)” | “8 (67)” | “16 (53)” |
| Sum of target lesion diameters >50 mm, No. (%) | “18 (43)” | “4 (33)” | “14 (47)” |
| Sum of target lesion diameters >70 mm, No. (%) | “11 (26)” | “3 (25)” | “8 (27)” |
| Prior radiotherapy in the LA HNSCC setting, No. (%) | “33 (79)” | “9 (75)” | “24 (80)” |
| Prior platinum-based chemotherapy, No. (%) | “27 (64)” | “12 (100)” | “15 (50)” |
First-line 1500 mg weekly cohort: prior curative-intent therapy
Dose escalation participants
Efficacy results
Dose escalation in advanced solid tumors: response in the combination arm
“With combination therapy, four of 13 evaluable patients (31%) had a confirmed response, including one with head and neck squamous cell carcinoma refractory to anti–PD-1 therapy and cetuximab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Four patients (HNSCC, n = 2; SCAC, n = 2) achieved a PR (Fig. 1D), with three of the four demonstrating a duration of response exceeding 2 years (range, 10.1–36.7 months), including one response that was ongoing at data cutoff.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Five patients achieved SD, resulting in an objective response rate of 31% (95% CI, 9%–61%) and a clinical benefit rate of 69% (95% CI, 39%–91%) for the combination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Data snapshot of 16 December 2024, 1500 mg weekly cohort: response and 12-month overall survival
Data snapshot of 20 March 2025, 1500 mg weekly cohort: follow-up
Data snapshot of 20 March 2025, 1500 mg weekly cohort: confirmed response in HPV-negative participants
Data snapshot of 20 March 2025, 1500 mg weekly cohort: response by combined positive score and disease pattern in HPV-negative participants
Data snapshot of 20 March 2025, 1500 mg weekly cohort: duration of and time to response
Data snapshot of 20 March 2025, 1500 mg weekly cohort: progression-free and overall survival by HPV status
Assessment of April 2025, 1500 mg weekly cohort: 24-month overall survival
Data snapshot of 20 March 2025, 1500 mg weekly cohort: survival by combined positive score and performance status
Data snapshot of 20 March 2025, 1500 mg weekly cohort: HPV-positive participants
Data snapshot of 9 July 2025, 750 mg weekly cohort: response
“ORR: 57% (17/30); CR: 10% (3/30)” (opens the source at this quote in a new tab)
“DCR: 83% (25/30)” (opens the source at this quote in a new tab)
“Median time to response: 1.6 months” (opens the source at this quote in a new tab)
“Deep response (≥80% tumor shrinkage): 29% (5/17)” (opens the source at this quote in a new tab)
Data snapshot of 9 July 2025, 750 mg weekly cohort: response by combined positive score and tumor burden
| Subgroup | Objective response rate |
|---|---|
| Combined positive score 1-19 | “73% (8/11)” |
| Combined positive score ≥20 | “47% (9/19)” |
| Sum of target lesion diameters ≤50 mm | “55% (11/20)” |
| Sum of target lesion diameters >50 mm | “60% (6/10)” |
| Sum of target lesion diameters >70 mm | “50% (2/4)” |
Data snapshot of 16 December 2025, 2000 mg every-2-weeks cohort: response
| Outcome | Efficacy-evaluable set (N=27) |
|---|---|
| Confirmed objective response rate | “48% (13/27)” |
| Disease control rate | “85% (23/27)” |
| Deep response among responders | “77% (10/13)” |
| Complete response rate | “26% (7/27)” |
| Median time to response | “1.6 months” |
| Objective response rate, combined positive score 1-19 | “57% (8/14)” |
| Objective response rate, combined positive score ≥20 | “39% (5/13)” |
Data snapshot of 16 December 2025, 750 mg and 1500 mg weekly cohorts: efficacy by cohort
| Outcome | Ficerafusp alfa 750 mg plus pembrolizumab (N=30) | Ficerafusp alfa 1500 mg plus pembrolizumab (N=28) |
|---|---|---|
| Confirmed objective response rate/complete response rate, n (%) | “17 (57)/4 (13)” | “15 (54)/6 (21)” |
| Responders with ≥80% shrinkage, n (%) | “8/17 (47)” | “12/15 (80)” |
| Median duration of response, months | “NR” | “21.7” |
| Proportion of responses >12 months, n (%) | “9/17 (53)” | “9/15 (60)” |
| Median progression-free survival, months | “6.9” | “9.9” |
Data snapshot of 16 December 2025, three cohorts: confirmed response and pooled depth of response
| Outcome | Tumor regression 0 to <80% (N=39) | Tumor regression ≥80%, deep response (N=31) |
|---|---|---|
| Median duration of response, months | “8.2” | “21.9” |
| Duration of response hazard ratio versus <80% regression (95% CI) | “N/A” | “0.27 [0.10, 0.71]” |
| Median progression-free survival, months | “6.5” | “26.4” |
| Progression-free survival hazard ratio (95% CI) | “N/A” | “0.19 [0.09, 0.40]” |
| Median overall survival, months | “14.9” | “NR” |
Data snapshot of 31 March 2026, three cohorts: analysis sets and follow-up
Data snapshot of 31 March 2026, three cohorts: response by cohort
| Outcome | Ficerafusp alfa 750 mg weekly | Ficerafusp alfa 1500 mg weekly | Ficerafusp alfa 2000 mg every 2 weeks |
|---|---|---|---|
| Confirmed objective response rate (95% CI) | “57% (37%-74%)” | “54% (34%-72%)” | “48% (29%-68%)” |
| Deep response among responders | “47% (8/17)” | “80% (12/15)” | “77% (10/13)” |
Data snapshot of 31 March 2026, three cohorts: company summary of efficacy by cohort
| Outcome | Ficerafusp alfa 750 mg weekly (n=30) | Ficerafusp alfa 1500 mg weekly (n=28) | Ficerafusp alfa 2000 mg every 2 weeks (n=27) |
|---|---|---|---|
| Confirmed overall response rate | “57%” | “54%” | “48%” |
| Complete response rate | “13%” | “25%” | “30%” |
| Deep (≥80%) responses | “47%” | “80%” | “77%” |
| Median time to response | “1.6 months” | “1.4 months” | “1.6 months” |
| Median duration of response | “NR (>16.6 months)” | “21.7 months” | “NR (>12.8 months)” |
| Median progression-free survival | “6.9 months” | “9.9 months” | “12.7 months” |
| Median overall survival | “NM (>19.4 months)” | “21.3 months” | “NM (>12.7 months; >23.6 months in patients with > 2-year follow-up)” |
Data snapshot of 31 March 2026, 1500 mg weekly cohort: response, duration of response, and 3-year overall survival
Data snapshot of 31 March 2026, three cohorts: progression-free and overall survival with confidence intervals
| Outcome | Ficerafusp alfa 750 mg weekly | Ficerafusp alfa 1500 mg weekly | Ficerafusp alfa 2000 mg every 2 weeks |
|---|---|---|---|
| Median progression-free survival (95% CI), months | “6.9 (4.6-NE)” | “9.9 (4.4-22.7)” | “12.7 (4.9-NE)” |
| Median overall survival (95% CI), months | “Not mature” | “21.3 (9.9-33.6)” | “Not mature” |
Data snapshot of 31 March 2026, three cohorts: confirmed response by combined positive score, tumor burden, and extent of disease
| Subgroup, % (n/N) | Ficerafusp alfa 750 mg weekly (n=30) | Ficerafusp alfa 1500 mg weekly (n=28) | Ficerafusp alfa 2000 mg every 2 weeks (n=27) |
|---|---|---|---|
| Combined positive score 1-19 | “73 (8/11)” | “54 (7/13)” | “57 (8/14)” |
| Combined positive score ≥20 | “47 (9/19)” | “53 (8/15)” | “38 (5/13)” |
| Sum of target lesion diameters ≤50 mm | “55 (11/20)” | “53 (8/15)” | “53 (9/17)” |
| Sum of target lesion diameters >50 mm | “60 (6/10)” | “54 (7/13)” | “40 (4/10)” |
| Sum of target lesion diameters >70 mm | “50 (2/4)” | “43 (3/7)” | “33 (2/6)” |
| Locoregional disease only | “38 (6/16)” | “62 (5/8)” | “50 (7/14)” |
| Distant metastatic disease only | “100 (5/5)” | “29 (2/7)” | “40 (2/5)” |
| Locoregional and distant metastatic disease | “67 (6/9)” | “62 (8/13)” | “50 (4/8)” |
Data snapshot of 31 March 2026, three cohorts pooled: outcomes by depth of response
Data snapshot of 31 March 2026, three cohorts pooled: median duration of response, progression-free survival, and overall survival by best response
| Best response group | Median duration of response (95% CI), months | Median progression-free survival (95% CI), months | Median overall survival (95% CI), months |
|---|---|---|---|
| Deep response (n=30) | “31.6 (21.6-NE)” | “36.9 (22.7-NE)” | “Not reached (26.3-NE)” |
| Partial response <80% (n=15) | “8.2 (4.0-NE)” | “10.9 (5.6-NE)” | “33.6 (10.9-NE)” |
Data snapshot of 31 March 2026, three cohorts pooled: progression-free and overall survival with stable or progressive disease
| Best response group | Median progression-free survival (95% CI), months | Median overall survival (95% CI), months |
|---|---|---|
| Stable disease (n=26) | “5.8 (3.6-6.8)” | “11.3 (9.0-20.6)” |
| Progressive disease (n=14) | “1.4 (1.3-1.5)” | “7.3 (2.4-17.1)” |
Health-related quality of life and patient-reported outcomes
Patient-reported outcomes not assessed in the 1500 mg weekly expansion cohort
Safety results
Dose escalation in advanced solid tumors: combination arm
“The MTD was not reached in either cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“TRAEs were reported for 87% (40 of 46) and 87% (13 of 15) of patients treated with ficerafusp alfa monotherapy and ficerafusp alfa in combination with pembrolizumab, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For ficerafusp alfa in combination with pembrolizumab, the most common TRAEs were acneiform dermatitis (73%; 11 of 15), fatigue (53%; eight of 15), epistaxis (40%; six of 15), pruritus (40%; six of 15), and maculopapular rash (40%; six of 15).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For ficerafusp alfa in combination with pembrolizumab, serious TRAEs included grade 3 anemia (n = 1), grade 3 stomatitis with grade 3 atrial fibrillation (n = 1), and grade 3 stomatitis with grade 3 pneumonitis (n = 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two patients treated with ficerafusp alfa in combination with pembrolizumab discontinued both drugs because of grade 3 reactive lichen planus and grade 3 atrial fibrillation, respectively. No grade 4 TRAEs or treatment-related deaths were observed in either cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Data snapshot of 20 March 2025, 1500 mg weekly cohort: summary of treatment-related adverse events
Data snapshot of 20 March 2025, 1500 mg weekly cohort: treatment-related adverse events by grade
| Treatment-related adverse event | Any grade | Grade 1/2 | Grade 3 | Grade 4 |
|---|---|---|---|---|
| Any treatment-related adverse event | “40 (95)” | “20 (48)” | “19 (45)” | “1 (2)” |
| Dermatitis acneiform | “32 (76)” | “27 (64)” | “5 (12)” | “0” |
| Fatigue | “19 (45)” | “18 (43)” | “1 (2)” | “0” |
| Pruritus | “18 (43)” | “17 (40)” | “1 (2)” | “0” |
| Anemia | “15 (36)” | “9 (21)” | “6 (14)” | “0” |
| Stomatitis | “11 (26)” | “9 (21)” | “2 (5)” | “0” |
| Infusion-related reaction | “8 (19)” | “7 (17)” | “1 (2)” | “0” |
| Epistaxis | “6 (14)” | “6 (14)” | “0” | “0” |
| Gingival bleeding | “6 (14)” | “6 (14)” | “0” | “0” |
| Colitis | “5 (12)” | “2 (5)” | “3 (7)” | “0” |
| Tracheal hemorrhage | “2 (5)” | “1 (2)” | “1 (2)” | “0” |
| Pericarditis | “1 (2)” | “0” | “0” | “1 (2)” |
Data snapshot of 20 March 2025, 1500 mg weekly cohort: overall incidence, interruptions, and discontinuations
Data snapshot of 20 March 2025, 1500 mg weekly cohort: dermatologic events including acneiform dermatitis
Data snapshot of 20 March 2025, 1500 mg weekly cohort: bleeding events
Data snapshot of 20 March 2025, 1500 mg weekly cohort: anemia and infusion-related reactions
Data snapshot of 20 March 2025, 1500 mg weekly cohort: treatment-emergent adverse events and deaths
Data snapshot of 9 July 2025, 750 mg weekly cohort: treatment-related adverse events
Data snapshot of 9 July 2025, 750 mg weekly cohort: discontinuations and deaths
| Safety outcome | Safety set (N=31) |
|---|---|
| Treatment-related adverse event leading to ficerafusp alfa discontinuation | “2 (6%)” |
Data snapshot of 16 December 2025, 2000 mg every-2-weeks cohort: treatment-emergent adverse events related to ficerafusp alfa
| Event | Any grade (N=30) | Grade 3 (N=30) |
|---|---|---|
| Any related treatment-emergent adverse event | “29 (97%)” | “16 (53%)” |
| Dermatitis acneiform | “24 (80%)” | “3 (10%)” |
| Anemia | “14 (47%)” | “8 (27%)” |
| Stomatitis | “11 (37%)” | “3 (10%)” |
| Pruritus | “11 (37%)” | “1 (3%)” |
| Nausea | “9 (30%)” | “1 (3%)” |
Data snapshot of 16 December 2025, 2000 mg every-2-weeks cohort: discontinuations, grade 4 and 5 events, and deaths
| Safety outcome | Safety set (N=30) |
|---|---|
| Treatment-related adverse event leading to ficerafusp alfa discontinuation | “3 (10%)” |
Data snapshot of 31 March 2026, three cohorts: treatment-related adverse events by grade and cohort
| Preferred term, n (%) | 750 mg weekly (N=31), any grade | 750 mg weekly, grade 3 | 1500 mg weekly (N=30), any grade | 1500 mg weekly, grade 3 | 2000 mg every 2 weeks (N=30), any grade | 2000 mg every 2 weeks, grade 3 |
|---|---|---|---|---|---|---|
| Any treatment-related adverse event | “31 (100)” | “11 (35)” | “28 (93)” | “15 (50)” | “29 (97)” | “16 (53)” |
| Dermatitis acneiform | “27 (87)” | “1 (3)” | “23 (77)” | “4 (13)” | “24 (80)” | “3 (10)” |
| Pruritus | “13 (42)” | “1 (3)” | “16 (53)” | “1 (3)” | “11 (37)” | “1 (3)” |
| Anemia | “8 (26)” | “3 (10)” | “13 (43)” | “7 (23)” | “15 (50)” | “8 (27)” |
| Fatigue | “13 (42)” | “0 (0)” | “11 (37)” | “1 (3)” | “12 (40)” | “1 (3)” |
| Stomatitis | “13 (42)” | “4 (13)” | “8 (27)” | “0” | “11 (37)” | “3 (10)” |
| Epistaxis | “11 (35)” | “1 (3)” | “5 (17)” | “0” | “12 (40)” | “0” |
| Mouth bleeding | “8 (26)” | “1 (3)” | “0” | “0” | “4 (13)” | “0” |
| Infusion-related reaction | “6 (19)” | “1 (3)” | “4 (13)” | “1 (3)” | “7 (23)” | “0” |
Data snapshot of 31 March 2026, three cohorts: discontinuations, grade 4 events, and deaths
Study limitations
Summary
BCA101X1101 is an open-label, nonrandomized, single-arm phase 1/1b trial with investigator-assessed response; the authors state that the single-arm design makes it “difficult to isolate the contribution of individual treatment components”, and comparisons with KEYNOTE-048 are cross-trial. The 1500 mg weekly cohort enrolled participants in the United States and Canada only, did not assess patient-reported outcomes, and did not routinely collect subsequent therapy. The three first-line dose cohorts were analyzed as separate HPV-negative expansion cohorts of 30, 28, and 27 evaluable participants under a Simon two-stage design, with PD-L1 CPS assessed locally by 22C3 “or other validated assay” and HPV-positive participants of the 1500 mg cohort excluded from the integrated analysis. Duration of response and OS are immature in the 750 mg weekly and 2000 mg every 2 weeks cohorts; in the 2000 mg cohort, 12 of 27 evaluable participants had a median follow-up of 11.7 months. The depth-of-response analysis was post hoc, with small subgroups and a threshold that is not validated. The dose-escalation results come from 15 combination-arm participants with heterogeneous tumors and prior therapy.
Single-arm design, limited geographic scope, and missing subsequent-therapy data
Open-label, nonrandomized design with investigator-assessed response
Cross-trial comparisons with historical controls
Immature duration of response and survival in the 750 mg and 2000 mg cohorts
Local PD-L1 testing and exclusion of HPV-positive participants from the dose-cohort analyses
Post hoc depth-of-response analysis with an unvalidated threshold
Small sample and heterogeneous population in dose escalation
FORTIFI-FLEX
Objective
Study aim in the ClinicalTrials.gov record
Main and secondary objectives in the EU trial record
Location and study date
Study dates in the ClinicalTrials.gov record
| Study characteristic | Quoted record |
|---|---|
| Study start (estimated) | “2026-09” |
| Primary completion (estimated) | “2028-03” |
| Study completion (estimated) | “2029-03” |
| First posted | “2026-09-08” |
| Sites | “This study has 7 locations” |
Study design
Open-label randomized phase 2 design in the ClinicalTrials.gov record
Study design in the second-quarter results press release
Study schema in the corporate presentation
Eligibility criteria
Exclusion criteria in the ClinicalTrials.gov record
HPV status determination in the EU trial record
Prior-therapy criteria in the EU trial record
Measurable disease and performance status in the EU trial record
Treatment
Treatment arms in the ClinicalTrials.gov record
Loading regimen for all participants in the ClinicalTrials.gov record
Study outcomes
Rationale for using progression-free survival rate in the maintenance phase as the primary endpoint
Primary endpoint in the ClinicalTrials.gov record
| Primary endpoint | Quoted record |
|---|---|
| Measure | “Proportion of participants in maintenance phase who are progression-free as assessed by blinded independent central review (BICR) per RECIST 1.1 and alive.” |
| Time frame | “Approximately 9 months.” |
Secondary endpoints in the ClinicalTrials.gov record
“Serum exposure of ficerafusp alfa.” (opens the source at this quote in a new tab)
“Overall Survival (OS)” (opens the source at this quote in a new tab)
“Time to maximum tumor shrinkage” (opens the source at this quote in a new tab)
“Incidence of ≥Grade 3 TEAEs” (opens the source at this quote in a new tab)
“Incidence of Serious adverse events (SAEs)” (opens the source at this quote in a new tab)
Deep response definition in the EU trial record
Regulatory basis for the alternate regimen in company documents
Basis in the every-two-week expansion cohort in the annual report
FDA dose-optimization guidance on activity endpoints for dosage comparisons
FDA endpoint guidance on progression-free survival
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment in the ClinicalTrials.gov record
Planned enrollment in the corporate presentation
Description of analysis sets
Maintenance-phase randomization in the ClinicalTrials.gov record
Maintenance-phase and overall-course analyses in the EU trial record
Results
Participant disposition
Enrollment status in the third-quarter results press release
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
FORTIFI-FLEX is open-label, with no masking. Randomization occurs only after the 12-week loading phase and includes only participants without progression, so the randomized comparison addresses maintenance dosing in that subset. Both arms receive ficerafusp alfa with pembrolizumab. The primary endpoint, the proportion of maintenance-phase participants alive and progression-free at approximately 9 months, is assessed by BICR. Planned enrollment is 160 participants, and no results have been reported.